Report of Foreign Issuer (6-k)
August 09 2019 - 8:53AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
August 2019
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On August 9, 2019, Akari Therapeutics, Plc
(the “Company”) issued a press release announcing new preclinical and human data demonstrating the potential benefits
of the dual inhibition of complement (C5) and leukotriene (LTB4) pathways by nomacopan for the treatment of pemphigoid diseases.
A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in the first,
third and fourth paragraphs of Exhibit 99.1 is hereby incorporated by reference into all effective
registration statements filed by the Company under the Securities Act of 1933.
Exhibit No.
99.1
|
Press Release dated August 9, 2019.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Akari Therapeutics, Plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
By:
|
/s/ Clive Richardson
|
|
|
Name:
|
Clive Richardson
|
|
|
|
Interim Chief Executive Officer and
Chief Operating Officer
|
Date: August 9, 2019
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Sep 2023 to Sep 2024